Medication Precautions and Safe Medication Guide for Canafenib/Encofenib (Betavir)

1. Overview of Drugs

Canafenib/Encorafenib (Encorafenib) is an oral small molecule BRAF inhibitor, mainly targeting patients carrying BRAF V600 mutations. Indications include melanoma, colorectal cancer and some non-small cell lung cancer. Its mechanism of action is by inhibiting BRAF kinase activity and blocking the MAPK/ERK signaling pathway, thereby reducing tumor cell proliferation and inducing apoptosis. Encofenib can be used alone or in combination with MEK inhibitors (such as Binimetinib) to improve efficacy and delay the occurrence of drug resistance. Due to their targeting properties and potential side effects, safe management before, during and after administration is critical.

2. Precautions before taking medication

Before initiating treatment with encofenib, patients should undergo a thorough evaluation. Including hematology, liver and kidney function, electrocardiogram and imaging tests to understand the patient's basic condition and assess the risks of medication. For patients with pre-existing cardiovascular disease, hepatic insufficiency, or abnormal renal function, the benefits and risks should be weighed under the guidance of a physician, and the dose may be adjusted or monitoring strengthened. In addition, encofenib is contraindicated in pregnant and breastfeeding women because the drug may cause potential harm to the fetus or infant. Female patients need to take effective contraceptive measures during medication and after discontinuation of medication, and male patients should also use contraceptive methods to prevent the medication from affecting reproductive health through sperm.

At the same time, doctors should be informed of other drugs that the patient is taking, especially CYP3A4 inhibitors or inducers, anticoagulants, antiarrhythmic drugs and drugs with a risk of QT interval prolongation. These drugs may affect the plasma concentration of encofenib, resulting in reduced efficacy or increased side effects. If necessary, the doctor will adjust the dose or monitor the blood concentration.

3. Safety monitoring during medication

During encofenib treatment, patients need to undergo regular hematology, liver and kidney function and electrocardiogram tests. Common adverse reactions include fever, rash, nausea, joint pain, fatigue, and increased liver function indicators. In severe cases, complications such as blood clots, arrhythmias, or skin cancer may occur. Especially when combined with MEK inhibitors, attention should be paid to monitoring cardiac function and ophthalmic symptoms (such as retinopathy) to detect and deal with potential risks in a timely manner.

In addition, patients should pay attention to lifestyle management during treatment, such as maintaining a regular schedule, eating a balanced diet, avoiding overexertion, and using sun protection. If persistent fever, obvious rash, jaundice or abnormal bleeding occurs, seek medical attention immediately. In the early stage of treatment, doctors usually conduct follow-up visits every 2 to 4 weeks to observe tolerance and efficacy. During the stable period, the follow-up interval can be appropriately extended, but blood and organ function assessments are still required every month or every two months.

4. Missed doses and dosage adjustments

If the patient misses a dose, it should be dealt with according to the time of the missed dose: if it is a long time before the next dose, the missed dose should be taken as soon as possible, and then the medication should be continued as planned; if the next dose is close, the missed dose should be skipped, and do not take a double dose at one time to avoid increasing the risk of side effects.

For patients with severe adverse reactions or abnormal hematology or liver function, doctors can adjust the dose or temporarily stop the drug according to the specific situation, and then resume treatment after the symptoms are relieved. At the same time, patients should record their medication status, review results and adverse reactions in detail to facilitate doctors to make individualized adjustments to improve efficacy and safety.

5. Follow-up and long-term management

During long-term medication, patients need to undergo regular imaging examinations (such as CT or MRI) to evaluate changes in tumor burden and efficacy. If signs of resistance appear during treatment, doctors may recommend combining other targeted drugs or adjusting the treatment plan. Patients should maintain close communication with their doctors and provide timely feedback on symptoms and adverse reactions so that they can be dealt with in a timely manner and ensure continuity of treatment.

In short, canafenib/Encofenib has significant anti-tumor effects, but rational drug use, safety monitoring and life management are equally important. Through pre-medication assessment, standardized medication taking, regular review and timely dosage adjustment, the treatment effect can be maximized while reducing the risk of potential side effects, providing safe and effective targeted therapy options for patients with BRAF mutation-positive tumors.

Reference materials:https://www.drugs.com/